JLE

Hépato-Gastro & Oncologie Digestive

MENU

Management of anemia in patients treated with chemotherapy for digestive cancer Volume 26, supplement 1, Octobre 2019

Figures


  • Figure 1

  • Figure 2

  • Figure 3

  • Figure 4

Tables

Authors
1 CHU Pontchaillou, Service des maladies de l’appareil digestif, 2 rue Henri Le Guilloux, 35000 Rennes
2 Faculté de Médecine, Université Rennes 1, Rennes
* Correspondance

Anemia, often of multifactorial origin, is a common problem in oncology since it affects more than half of cancer patients and approximately two thirds of patients receiving chemotherapy. It has multiple consequences: it causes many and varied symptoms, the main one is fatigue and it affects the quality of life of patients. In addition, it is associated with a lower response to treatment and decreased overall survival in cancer patients. In digestive oncology, grade ≥3 anemia is generally less than 10% with the chemotherapy regimens used but grade 2 anemia (<10 g/dL) is observed in 25% to 50% of patients. The management of this chemotherapy-induced anemia is based on the research and the systematic correction of iron deficiency or any other cause of anemia and on the use of erythropoiesis stimulating agents (ESA) in case of Hb <8 g/dL or symptomatic anemia with Hb <10 g/dL Prescribing modalities, contraindications and follow-up of ESA should be in accordance with the recommendations of the ESMO (European Society for Medical Oncology) and good use of drugs of HAS (Haute Autorité de Santé). There are many equivalent molecules. Efficacy should be regularly re-evaluated and treatment should be discontinued after 8 weeks in case of ineficiency.

Licence This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License